Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects

Puma Biotechnology

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: neratinib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00498745

3144A1-1109

Details and patient eligibility

About

To evaluate the comparative bioavailability of 2 new tablet formulations of HKI-272 with a reference capsule and an oral solution in healthy subjects.

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Criteria:

• Healthy male and female subjects aged 18 to 50 years.
• Women of nonchildbearing potential (WONCBP)